nach oben

Erschienen in:

01.02.2018 | Case Report

A case of atypical hemolytic uremic syndrome in a second renal transplant

verfasst von: Nicholas A. Zwang, Bing Ho, Yashpal S. Kanwar, Brad Lewis, Matthew Cusick, John J. Friedewald, Lorenzo Gallon

Erschienen in: Journal of Nephrology | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Atypical hemolytic uremic syndrome (aHUS) has gained increased visibility over several years as an important cause of renal failure. Unfortunately, diagnosis is often difficult because individual courses can be highly variable depending the causative genetic mutations. Here we present the case of a patient with a failed renal allograft and acute failure of a second allograft who was ultimately diagnosed with aHUS. Interestingly, he developed early de novo donor specific antibodies (DSA) after the second renal transplant in context of likely recurrent aHUS. Terminal complement inhibition with eculizumab resulted in prompt improvement of renal allograft function.

Nur mit Berechtigung zugänglich

Recipient HLA typing was as follows: A11, A24, B18, B35, DR4, DR53 (there was no C, DQ or DP tying for the recipient). Donor HLA typing was as follows: A2, A68, B53, C4, DR13, DR16, DQ2, and DQ5 (there was no donor DP typing).

Recipient HLA typing was as follows: A11, A24, B18, B35, DR4, DR53 (there was no C, DQ or DP tying for the recipient). Donor HLA typing was as follows: A1, A24, B7, B62, C7, C10, DR4, DR53, DQ8, DP3, and DP14. There was no history of Class II donor specific antibodies pre- or post-transplant.

Sellier-Leclerc AL, Fremeaux-Bacchi V, Dragon-Durey MA, Macher MA, Niaudet P, Guest G, Boudailliez B, Bouissou F, Deschenes G, Gie S, Tsimaratos M, Fischbach M, Morin D, Nivet H, Alberti C, Loirat C (2007) Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. J Am Soc Nephrol JASN 18(8):2392–2400. doi:10.1681/asn.2006080811 CrossRefPubMed

Noris M, Caprioli J, Bresin E, Mossali C, Pianetti G, Gamba S, Daina E, Fenili C, Castelletti F, Sorosina A, Piras R, Donadelli R, Maranta R, van der Meer I, Conway EM, Zipfel PF, Goodship TH, Remuzzi G (2010) Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol CJASN 5(10):1844–1859. doi:10.2215/cjn.02210310 CrossRefPubMed

Dragon-Durey MA, Fremeaux-Bacchi V, Loirat C, Blouin J, Niaudet P, Deschenes G, Coppo P, Herman Fridman W, Weiss L (2004) Heterozygous and homozygous factor h deficiencies associated with hemolytic uremic syndrome or membranoproliferative glomerulonephritis: report and genetic analysis of 16 cases. J Am Soc Nephrol JASN 15(3):787–795CrossRefPubMed

Laurence J (2012) Atypical hemolytic uremic syndrome (aHUS): making the diagnosis. Clin Adv Hematol Oncol H O 10(10 Suppl 17):1–12PubMed

Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, Bingham C, Cohen DJ, Delmas Y, Douglas K, Eitner F, Feldkamp T, Fouque D, Furman RR, Gaber O, Herthelius M, Hourmant M, Karpman D, Lebranchu Y, Mariat C, Menne J, Moulin B, Nurnberger J, Ogawa M, Remuzzi G, Richard T, Sberro-Soussan R, Severino B, Sheerin NS, Trivelli A, Zimmerhackl LB, Goodship T, Loirat C (2013) Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 368(23):2169–2181. doi:10.1056/NEJMoa1208981 CrossRefPubMed

Rougier N, Kazatchkine MD, Rougier JP, Fremeaux-Bacchi V, Blouin J, Deschenes G, Soto B, Baudouin V, Pautard B, Proesmans W, Weiss E, Weiss L (1998) Human complement factor H deficiency associated with hemolytic uremic syndrome. J Am Soc Nephrol JASN 9(12):2318–2326PubMed

Warwicker P, Goodship TH, Donne RL, Pirson Y, Nicholls A, Ward RM, Turnpenny P, Goodship JA (1998) Genetic studies into inherited and sporadic hemolytic uremic syndrome. Kidney Int 53(4):836–844. doi:10.1111/j.1523-1755.1998.00824.x CrossRefPubMed

Fremeaux-Bacchi V, Dragon-Durey MA, Blouin J, Vigneau C, Kuypers D, Boudailliez B, Loirat C, Rondeau E, Fridman WH (2004) Complement factor I: a susceptibility gene for atypical haemolytic uraemic syndrome. J Med Genet 41(6):e84CrossRefPubMedPubMedCentral

Skerka C, Chen Q, Fremeaux-Bacchi V, Roumenina LT (2013) Complement factor H related proteins (CFHRs). Mol Immunol 56(3):170–180. doi:10.1016/j.molimm.2013.06.001 CrossRefPubMed

10.

de Jorge EG, Macor P, Paixao-Cavalcante D, Rose KL, Tedesco F, Cook HT, Botto M, Pickering MC (2011) The development of atypical hemolytic uremic syndrome depends on complement C5. J Am Soc Nephrol JASN 22(1):137–145. doi:10.1681/asn.2010050451 CrossRefPubMed

11.

Le Quintrec M, Roumenina L, Noris M, Fremeaux-Bacchi V (2010) Atypical hemolytic uremic syndrome associated with mutations in complement regulator genes. Semin Thromb Hemost 36(6):641–652. doi:10.1055/s-0030-1262886 CrossRefPubMed

12.

Maga TK, Nishimura CJ, Weaver AE, Frees KL, Smith RJ (2010) Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome. Hum Mutat 31(6):E1445–E1460. doi:10.1002/humu.21256 CrossRefPubMed

13.

Bienaime F, Dragon-Durey MA, Regnier CH, Nilsson SC, Kwan WH, Blouin J, Jablonski M, Renault N, Rameix-Welti MA, Loirat C, Sautes-Fridman C, Villoutreix BO, Blom AM, Fremeaux-Bacchi V (2010) Mutations in components of complement influence the outcome of factor I-associated atypical hemolytic uremic syndrome. Kidney Int 77(4):339–349. doi:10.1038/ki.2009.472 CrossRefPubMed

14.

Zipfel PF, Edey M, Heinen S, Jozsi M, Richter H, Misselwitz J, Hoppe B, Routledge D, Strain L, Hughes AE, Goodship JA, Licht C, Goodship TH, Skerka C (2007) Deletion of complement factor H-related genes CFHR1 and CFHR3 is associated with atypical hemolytic uremic syndrome. PLoS Genet 3(3):e41. doi:10.1371/journal.pgen.0030041 CrossRefPubMedPubMedCentral

15.

Thomas TC, Rollins SA, Rother RP, Giannoni MA, Hartman SL, Elliott EA, Nye SH, Matis LA, Squinto SP, Evans MJ (1996) Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv. Mol Immunol 33(17–18):1389–1401CrossRefPubMed

16.

Rathbone J, Kaltenthaler E, Richards A, Tappenden P, Bessey A, Cantrell A (2013) A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS). BMJ open 3(11):e003573. doi:10.1136/bmjopen-2013-003573 CrossRefPubMedPubMedCentral

17.

Salant DJ (2011) Targeting complement C5 in atypical hemolytic uremic syndrome. J Am Soc Nephrol JASN 22(1):7–9. doi:10.1681/asn.2010111145 CrossRefPubMed

18.

Al-Akash SI, Almond PS, Savell VH Jr, Gharaybeh SI, Hogue C (2011) Eculizumab induces long-term remission in recurrent post-transplant HUS associated with C3 gene mutation. Pediatr Nephrol (Berlin, Germany) 26(4):613–619. doi:10.1007/s00467-010-1708-6 CrossRef

19.

Chatelet V, Fremeaux-Bacchi V, Lobbedez T, Ficheux M, Hurault de Ligny B (2009) Safety and long-term efficacy of eculizumab in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome. Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg 9(11):2644–2645. doi:10.1111/j.1600-6143.2009.02817.x CrossRef

20.

Davin JC, Gracchi V, Bouts A, Groothoff J, Strain L, Goodship T (2010) Maintenance of kidney function following treatment with eculizumab and discontinuation of plasma exchange after a third kidney transplant for atypical hemolytic uremic syndrome associated with a CFH mutation. Am J Kidney Dis Off J Nat Kidney Found 55(4):708–711. doi:10.1053/j.ajkd.2009.08.011 CrossRef

21.

Chandran S, Baxter-Lowe L, Olson JL, Tomlanovich SJ, Webber A (2011) Eculizumab for the treatment of de novo thrombotic microangiopathy post simultaneous pancreas-kidney transplantation–a case report. Transplant Proc 43(5):2097–2101. doi:10.1016/j.transproceed.2011.02.064 CrossRefPubMed

22.

Sartelet H, Toupance O, Lorenzato M, Fadel F, Noel LH, Lagonotte E, Birembaut P, Chanard J, Rieu P (2005) Sirolimus-induced thrombotic microangiopathy is associated with decreased expression of vascular endothelial growth factor in kidneys. Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg 5(10):2441–2447. doi:10.1111/j.1600-6143.2005.01047.x CrossRef

23.

Reynolds JC, Agodoa LY, Yuan CM, Abbott KC (2003) Thrombotic microangiopathy after renal transplantation in the United States. Am J Kidney Dis Off J Nat Kidney Found 42(5):1058–1068CrossRef

24.

Langer RM, Van Buren CT, Katz SM, Kahan BD (2002) De novo hemolytic uremic syndrome after kidney transplantation in patients treated with cyclosporine-sirolimus combination. Transplantation 73(5):756–760CrossRefPubMed

25.

Robson M, Cote I, Abbs I, Koffman G, Goldsmith D (2003) Thrombotic micro-angiopathy with sirolimus-based immunosuppression: potentiation of calcineurin-inhibitor-induced endothelial damage? Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg 3(3):324–327CrossRef

26.

Fortin MC, Raymond MA, Madore F, Fugere JA, Paquet M, St-Louis G, Hebert MJ (2004) Increased risk of thrombotic microangiopathy in patients receiving a cyclosporin-sirolimus combination. Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg 4(6):946–952. doi:10.1111/j.1600-6143.2004.00428.x CrossRef

27.

Dhakal P, Giri S, Pathak R, Bhatt VR (2015) Eculizumab in transplant-associated thrombotic microangiopathy. Clin Appl Thromb/Hemost Off J Intl Acad Clin Appl Thromb Hemost. doi:10.1177/1076029615599439

28.

Wiebe C, Gibson IW, Blydt-Hansen TD, Karpinski M, Ho J, Storsley LJ, Goldberg A, Birk PE, Rush DN, Nickerson PW (2012) Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg 12(5):1157–1167. doi:10.1111/j.1600-6143.2012.04013.x CrossRef

29.

Smith RN, Kawai T, Boskovic S, Nadazdin O, Sachs DH, Cosimi AB, Colvin RB (2008) Four stages and lack of stable accommodation in chronic alloantibody-mediated renal allograft rejection in Cynomolgus monkeys. Am J transplant Off J Am Soc Transplant Am Soc Transplant Surg 8(8):1662–1672. doi:10.1111/j.1600-6143.2008.02303.x CrossRef

30.

Loupy A, Lefaucheur C, Vernerey D, Prugger C, Duong van Huyen JP, Mooney N, Suberbielle C, Fremeaux-Bacchi V, Mejean A, Desgrandchamps F, Anglicheau D, Nochy D, Charron D, Empana JP, Delahousse M, Legendre C, Glotz D, Hill GS, Zeevi A, Jouven X (2013) Complement-binding anti-HLA antibodies and kidney-allograft survival. N Engl J Med 369(13):1215–1226. doi:10.1056/NEJMoa1302506 CrossRefPubMed

31.

Steele DJ, Laufer TM, Smiley ST, Ando Y, Grusby MJ, Glimcher LH, Auchincloss H Jr (1996) Two levels of help for B cell alloantibody production. J Exp Med 183(2):699–703CrossRefPubMed

32.

Vella JP, Spadafora-Ferreira M, Murphy B, Alexander SI, Harmon W, Carpenter CB, Sayegh MH (1997) Indirect allorecognition of major histocompatibility complex allopeptides in human renal transplant recipients with chronic graft dysfunction. Transplantation 64(6):795–800CrossRefPubMed

33.

Sacks SH, Zhou W (2012) The role of complement in the early immune response to transplantation. Nat Rev Immunol 12(6):431–442. doi:10.1038/nri3225 CrossRefPubMed

34.

Zhou W, Farrar CA, Abe K, Pratt JR, Marsh JE, Wang Y, Stahl GL, Sacks SH (2000) Predominant role for C5b-9 in renal ischemia/reperfusion injury. J Clin Invest 105(10):1363–1371. doi:10.1172/jci8621 CrossRefPubMedPubMedCentral

35.

Weisman HF, Bartow T, Leppo MK, Marsh HC Jr, Carson GR, Concino MF, Boyle MP, Roux KH, Weisfeldt ML, Fearon DT (1990) Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science 249(4965):146–151CrossRefPubMed

36.

Evans PR, Trickett LP, Smith JL, MacIver AG, Tate D, Slapak M (1985) Varying expression of major histocompatibility complex antigens on human renal endothelium and epithelium. Br J Exp pathol 66(1):79–87PubMedPubMedCentral

37.

Bishop GA, Hall BM, Suranyi MG, Tiller DJ, Horvath JS, Duggin GG (1986) Expression of HLA antigens on renal tubular cells in culture. I. Evidence that mixed lymphocyte culture supernatants and gamma interferon increase both class I and class II HLA antigens. Transplantation 42(6):671–679CrossRefPubMed

38.

Locke JE, Zachary AA, Warren DS, Segev DL, Houp JA, Montgomery RA, Leffell MS (2009) Proinflammatory events are associated with significant increases in breadth and strength of HLA-specific antibody. Am J Transplant Off J Amn Soc Transplant Am Soc Transplant Surg 9(9):2136–2139. doi:10.1111/j.1600-6143.2009.02764.x CrossRef

Titel: A case of atypical hemolytic uremic syndrome in a second renal transplant
verfasst von: Nicholas A. Zwang
Bing Ho
Yashpal S. Kanwar
Brad Lewis
Matthew Cusick
John J. Friedewald
Lorenzo Gallon
Publikationsdatum: 01.02.2018
Verlag: Springer International Publishing
Erschienen in: Journal of Nephrology / Ausgabe 1/2018
Print ISSN: 1121-8428
Elektronische ISSN: 1724-6059
DOI: https://doi.org/10.1007/s40620-016-0373-7

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Bei Herzinsuffizienz muss „Eisenmangel“ neu definiert werden!

16.05.2024 Herzinsuffizienz Nachrichten

Bei chronischer Herzinsuffizienz macht es einem internationalen Expertenteam zufolge wenig Sinn, die Diagnose „Eisenmangel“ am Serumferritin festzumachen. Das Team schlägt vor, sich lieber an die Transferrinsättigung zu halten.

Herzinfarkt mit 85 – trotzdem noch intensive Lipidsenkung?

16.05.2024 Hypercholesterinämie Nachrichten

Profitieren nach einem akuten Myokardinfarkt auch Betroffene über 80 Jahre noch von einer intensiven Lipidsenkung zur Sekundärprävention? Um diese Frage zu beantworten, wurden jetzt Registerdaten aus Frankreich ausgewertet.

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Manifestiert sich ein Typ-1-Diabetes bei Kindern, ist das ein Notfall – ebenso wie eine diabetische Ketoazidose. Die Grundsäulen der Therapie bestehen aus Rehydratation, Insulin und Kaliumgabe. Insulin ist das Medikament der Wahl zur Behandlung der Ketoazidose.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2018

Recommendations for the treatment of hepatitis C virus infection in chronic kidney disease: a position statement by the Spanish association of the liver and the kidney

Incidence and characteristics of chronic renal replacement therapy in patients with cancer: data from kidney and cancer registries in Basse-Normandie

Dialysate temperature of 36 °C: association with clinical outcomes

Cisplatin nephrotoxicity: a review of the literature

CKD complications in kidney-transplanted patients going back to dialysis: impact on patients outcomes